RLS102

RLS102 is an orally administered **synthetic cannabidiol** capsule being developed by Receptor Life Sciences for **irritability associated with autism spectrum disorder**. It is described as a first-in-class small molecule product that combines pure synthetic cannabidiol with **SNAC** oral absorption technology to improve gastrointestinal uptake versus conventional solid oral CBD formulations. In early clinical work, the formulation showed substantially increased cannabidiol exposure relative to standard solid oral CBD products, supporting its development as a differentiated oral CBD therapy for neurobehavioral symptoms in autism spectrum disorder. Its pharmacology is expected to derive from cannabidiol-mediated modulation of the **endocannabinoid system**, although the precise therapeutic target and clinically relevant mechanism for ASD-associated irritability have not been fully defined publicly.

Other names

synthetic cannabidiolCBD